The overall goal of this proposal is to understand how the serine/threonine protein kinase Akt cooperates with other oncogenic/tumor survival pathways to cause breast cancer, and to develop preclinically and clinically novel combination therapies for more effective breast cancer treatment. Overexpression of receptor tyrosine kinases such as ErbB2, which leads to persistent hyperactivation of a large number of oncogenic/tumor survival proteins such as Ras, Rho, Ral, Akt, MEK and STAT3, is associated with poor prognosis, resistance to chemotherapy and shortened survival time of breast cancer patients. This prompted the development of novel agents such as the ErbB2 antibody Herceptin and small molecule inhibitors of the activation of Akt (Triciribine (TCN/TCN-P)), MEK (CI-1040), Ras and other farnesylated proteins (Tipifarnib) and Rho and other geranylgeranylated proteins (GGTI-2417). A large body of evidence implicates Akt in cancer development and maintenance, but interfering with Akt alone does not appear to be sufficient, suggesting that blocking other pathways in combination with Akt inactivation is critical to thwarting breast cancer. For example, inactivation of Akt with TCN in combination with either Tipifarnib or GGTI-2417 is synergistic, suggesting that Akt cooperates with farnesylated and geranylgeranylated (prenylated) proteins yet to be identified, to cause breast cancer. In this application we propose to use high throughput screens based on RNA interference to identify these prenylated proteins and to develop novel combination therapies for breast cancer. The hypothesis to be tested is that hyperactivated Akt cooperates with prenylated proteins to contribute to breast oncogenesis and tumor resistance, and that targeted intervention of Akt in combination with other anti-signaling and cytotoxic agents suppresses tumor growth and induces apoptosis in breast tumors.
The specific aims are: 1) To identify prenylated proteins whose knockdown sensitizes breast cancer cells to inactivation of Akt by TCN, 2) To identify specific prenylated proteins whose knockdown sensitizes breast cancer cells to the knock down of the three Akt isoforms, Akt1, Akt2 or Akt3, 3) To determine if inactivation of Akt by TCN sensitizes human breast tumors to cytotoxic and anti-signaling agents relevant to breast cancer treatment and, 4) To conduct hypothesis-driven phase I/II clinical trials of pre-operative TCN-P plus weekly paclitaxel and Tipifarnib followed by AC plus Tipifarnib in patients with locally advanced and metastatic breast cancer. Results from these studies will lead to the identification of oncogenic/tumor survival prenylated proteins that cooperate with Akt to cause breast cancer as well as to the design of novel combination therapies that will improve breast cancer survival by increasing the cure rate in patients with locally advanced breast cancer.

Public Health Relevance

The overall goal of this proposal is to develop combination therapies to improve breast cancer survival by increasing the cure rate in patients with locally advanced breast cancer. This will be done by: i) identifying novel proteins that cooperate with the protein Akt to cause breast cancer and ii) developing inhibitors of such proteins. Clinical trials will be performed to evaluate the efficacy of the drug combinations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA098473-08
Application #
8264947
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Song, Min-Kyung H
Project Start
2003-06-13
Project End
2015-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
8
Fiscal Year
2012
Total Cost
$310,370
Indirect Cost
$120,025
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Zhang, X; Blaskovich, M A; Forinash, K D et al. (2014) Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours. Br J Cancer 111:894-902
Yang, Hua; Lawrence, Harshani R; Kazi, Aslamuzzaman et al. (2014) Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation. Oncotarget 5:2947-61
Patel, R A; Liu, Y; Wang, B et al. (2014) Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities. Oncogene 33:550-5
Andreopoulou, Eleni; Vigoda, Ivette S; Valero, Vicente et al. (2013) Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma. Breast Cancer Res Treat 141:429-35
Hodul, Pamela J; Dong, Yanbin; Husain, Kazim et al. (2013) Vitamin E ?-tocotrienol induces p27(Kip1)-dependent cell-cycle arrest in pancreatic cancer cells via an E2F-1-dependent mechanism. PLoS One 8:e52526
Berndt, Norbert; Patel, Ronil; Yang, Hua et al. (2013) Akt2 and acid ceramidase cooperate to induce cell invasion and resistance to apoptosis. Cell Cycle 12:2024-32
Berndt, Norbert; Sebti, Said M (2011) Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors. Nat Protoc 6:1775-91
Balasis, Maria E; Forinash, Kara D; Chen, Y Ann et al. (2011) Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice. Clin Cancer Res 17:2852-62
Berndt, Norbert; Hamilton, Andrew D; Sebti, Said M (2011) Targeting protein prenylation for cancer therapy. Nat Rev Cancer 11:775-91
Berndt, N; Yang, H; Trinczek, B et al. (2010) The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane. Cell Death Differ 17:1795-804

Showing the most recent 10 out of 14 publications